First cell therapy trial for Huntington’s disease begins

A major milestone in regenerative medicine: first cell therapy trial for Huntington’s disease begins

An update on the first clinical trial evaluating a pluripotent stem cell-derived neural stem cell therapy for Huntington’s disease was presented at the ISSCR 2026 Annual Meeting. The study marks an important milestone in the development of regenerative medicine.

The phase 1b/2a Regen4HD study follows years of preclinical research, safety testing, and regulatory engagement. It aims to develop new therapeutic approaches for Huntington’s disease, a condition for which no disease-modifying treatments are currently available.

Huntington’s disease is a progressive neurodegenerative disorder. Regenerative approaches based on human stem cell-derived products are being explored as a potential way to influence disease pathology and address a significant unmet medical need.

Regen4HD is enrolling patients aged 18 to 65 with relatively early-stage symptomatic disease. The phase 1b portion is a dose-escalation study designed to assess the safety and tolerability of the therapy. It will be followed by a phase 2a stage aimed at determining the maximum tolerated dose.

Researchers emphasize that the initial goal of the study is to establish safety. If future studies demonstrate that a one-time cell therapy can slow disease progression, it could have meaningful implications for people living with Huntington’s disease. This clinical trial opens new prospects in regenerative medicine, cell therapy, and the treatment of neurodegenerative diseases.